The Treatment of Bladder Cancer
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, discusses the treatment of bladder cancer.
Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute and professor of Medicine at the Cleveland Clinic in Ohio, discusses the treatment of bladder cancer.
Clinical Pearls
Bladder cancer has been difficult to treat for two reasons: It is an aggressive epithelial cancer and has been treated primarily with chemotherapy. MLN8237 and other compounds are being looked at in phase II studies to generate enthusiasm for phase III trials.
- Bladder cancer is an aggressive epithelial cancer and has been primarily treated with chemotherapy
- MLN8237 and other compounds are in phase II studies, looking to generate enthusiasm for large phase III trials
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
